Celularity Inc. (NASDAQ:CELU) Sees Significant Growth in Short Interest

Celularity Inc. (NASDAQ:CELU) was the recipient of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,040,000 shares, a growth of 261.9% from the February 13th total of 287,400 shares. Approximately 8.3% of the company’s shares are short sold. Based on an average daily trading volume, of 170,300 shares, the days-to-cover ratio is presently 6.1 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP acquired a new position in Celularity during the 4th quarter worth about $93,000. Biltmore Family Office LLC acquired a new position in Celularity during the 4th quarter worth about $73,000. C V Starr & Co. Inc. acquired a new position in Celularity during the 4th quarter worth about $1,589,000. Finally, Keynote Financial Services LLC lifted its holdings in Celularity by 90.1% during the 4th quarter. Keynote Financial Services LLC now owns 25,023 shares of the company’s stock worth $52,000 after buying an additional 11,863 shares during the period. 19.02% of the stock is owned by institutional investors and hedge funds.

Celularity Stock Up 17.2 %

Shares of CELU opened at $1.57 on Thursday. Celularity has a 12 month low of $1.00 and a 12 month high of $6.05. The stock’s 50-day moving average price is $1.95 and its two-hundred day moving average price is $2.32.

About Celularity

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.